Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.
CEO
Chairman Of The Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Igor Lokot | 29,09 | 43,77 | 2020-03-31 |
| Avanza Pension | 6,53 | 5,32 | 2020-09-30 |
| Obain AB | 2,66 | 2,17 | 2020-09-30 |
| Per Ahlström | 2,64 | 2,16 | 2020-09-30 |
| Magnus Hamberg | 2,29 | 1,87 | 2020-09-30 |
| Jan Johan Paalberg | 2,11 | 1,72 | 2020-09-30 |
| Unwrap Finance Nordic AB | 1,78 | 1,45 | 2020-09-30 |
| Rejo AB | 1,66 | 1,35 | 2020-09-30 |
| KSDR Hamberg AB | 1,53 | 1,25 | 2020-09-30 |
| Kerstin Gunilla Paalberg | 1,21 | 0,99 | 2020-09-30 |
2021-02-25 Bokslutskommuniké 2020
2021-05-04 Delårsrapport 2021-Q1